Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bora Pharmaceuticals Co., Ltd. (6472.TW)
Taipei City, TW
Globally, Bora Pharmaceuticals Co., LTD. is engaged in the comprehensive lifecycle of pharmaceutical products, encompassing research and development, manufacturing, distribution, and sales. The organization operates through key divisions, including Sales, Contract Development & Manufacturing Organization (CDMO), and other ancillary services. Bora produces and markets a diverse range of medicines, from generic and proprietary brand-name drugs to over-the-counter (OTC) remedies. Beyond its in-house portfolio, the company provides extensive contract development and manufacturing solutions. These CDMO services cover all stages of pharmaceutical development, clinical and commercial production, specialized packaging and serialization, rigorous analytical and microbiological quality control, and expert guidance on regulatory compliance. Furthermore, Bora's offerings extend to nutritional supplements, skincare products, and various biotechnical services. The company distributes its goods directly to healthcare facilities such as clinics, pharmacies, and pharmacy chains, as well as to drugstores. It also leverages distributors to supply larger institutions like medical centers, corporate and public hospitals, and regional and district hospitals. Established in 2007, Bora Pharmaceuticals Co., LTD. is based in Taipei City, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +5.24% | -11.34% | -10.70% | -25.10% | -33.78% | -23.87% | -37.96% | -28.16% | -28.16% | -28.16% | -28.16% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 1 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-1.2% Q1'26: -10.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-22.2% Q1'26: -98.1% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+22.0% ★ Q1'26: +8.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+17.3% ★ Q1'26: +10.2% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+9.1% ★ Q1'26: +3.3% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+8.0% Q1'26: -3.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×4.31× Q1'26: 6.49× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
14.20B
est: 14.19B (+0.1%)
|
19.25B
est: 19.39B (-0.8%)
|
19.01B
est: 19.30B (-1.5%)
|
21.31B
18.70B – 23.46B
+10.4% YoY
|
30.40B
24.28B – 35.42B
+42.6% YoY
|
| EBITDA |
5.73B
est: 4.04B (+42.0%)
|
6.46B
est: 4.75B (+36.0%)
|
4.23B
est: 4.73B (-10.5%)
|
5.22B
4.58B – 5.74B
+10.4% YoY
|
7.44B
5.95B – 8.67B
+42.6% YoY
|
| EBIT |
5.25B
est: 3.36B (+56.3%)
|
5.43B
est: 3.44B (+58.0%)
|
3.29B
est: 3.42B (-3.8%)
|
3.78B
3.32B – 4.16B
+10.4% YoY
|
5.39B
4.31B – 6.28B
+42.6% YoY
|
| Net Income |
3.03B
est: 3.34B (-9.4%)
|
3.94B
est: 4.65B (-15.3%)
|
2.98B
est: 4.38B (-32.0%)
|
3.29B
2.80B – 3.77B
-25.0% YoY
|
5.45B
4.24B – 6.66B
+65.8% YoY
|
| SGA |
1.44B
est: 2.09B (-31.0%)
|
3.63B
est: 2.70B (+34.5%)
|
3.89B
est: 2.69B (+44.6%)
|
2.97B
2.60B – 3.27B
+10.4% YoY
|
4.23B
3.38B – 4.93B
+42.6% YoY
|
| EPS |
25.19
est: 26.60 (-5.3%)
|
32.14
est: 34.25 (-6.2%)
|
23.90
est: 29.31 (-18.4%)
|
24.56
20.64 – 27.77
-16.2% YoY
|
40.62
31.25 – 49.05
+65.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.08% | 56.6K | 0.74% |
| 2 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.07% | 259.0K | 0.72% |
| 3 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.06% | 200.2K | 0.74% |
| 4 | WisdomTree Emerging Markets SmallCap Dividend Fund DGS | 0.05% | 898.0K | 0.58% |
| 5 | WisdomTree Emerging Markets SmallCap Dividend UCITS ETF DGSD.L | 0.05% | 22.0K | 0.54% |
| 6 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.04% | 53.4K | 0.42% |
| 7 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.04% | 244.1K | 0.55% |
| 8 | Dimensional - Emerging Markets Value ETF DFEV | 0.02% | 428.5K | 0.46% |
| 9 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.02% | 2.65M | 0.06% |
| 10 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.01% | 91.1K | 0.44% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Alice Wang | Chief Financial Officer of HQ & APAC | — | female |
| Ellen Chen | Corporate Human Resource Director | — | female |
| Marcel Vieno | Chief Financial Officer of North America | — | male |
| Pao-Shi Sheng | Chairman, GM & Chief Executive Officer | — | male |
| Sally Langa | Senior Vice President of Marketing and Sales - CDMO Business | — | female |
| Shih-Min Chen | Vice President & Director | — | male |
| Tom Chang | Senior Vice President of Taiwan Site Operations | — | — |
| Xiaoting Chen | Accounting Supervisor | — | — |
| Xiu-Rong Zhang | Deputy General Manager | — | — |
| Zhen-Tang Zhang | Deputy General Manager | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6472.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
